A COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB 300 MG VS CURRENT THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ITALY

被引：6
|
作者：
D'Ausilio, A. [1 ]
Aiello, A. [1 ]
Daniel, F. [1 ]
Graham, C. [2 ]
Roccia, A. [3 ]
Toumi, M. [4 ]
机构：
[1] Creativ Ceut, Milan, Italy
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] Novartis Farma SpA, Origgio, Italy
[4] Aix Marseille Univ, Marseille, France
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.574
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS50
引用
收藏
页码：A424 / A424
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO CURRENT BIOLOGICS SEQUENCES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
    Duteil, E.
    Cariou, C.
    Schmidt, A.
    Benjamin, K.
    Duco, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [2] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
    Klimes, J.
    Mollon, P.
    Graham, C.
    Rajnoch, J.
    Dostal, F.
    Skalicky, D.
    Jordan, P.
    Depta, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [3] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [4] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [5] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [6] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [7] The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
    Nyholm, Nanna
    Dansa, Anne
    Schnack, Henrik
    Colombo, Giorgio Lorenzo
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 607 - 619
  • [8] COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GERMANY
    Betts, K.
    Yan, Y.
    Sundaram, M.
    Hengst, N.
    Wolff, M.
    Bensimon, A. G.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A570 - A570
  • [9] Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
    Gisondi, Paolo
    Loconsole, Francesco
    Raimondo, Paola
    Ravasio, Roberto
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 120 - 130
  • [10] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S422 - S422
12345